Core Viewpoint - Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025 [2] Group 1 - The drug registration certificate is a significant regulatory milestone for the company, indicating approval for the injectable formulation of isavuconazole [2] - This approval may enhance the company's product portfolio and market presence in the pharmaceutical industry [2] - The announcement reflects the company's ongoing commitment to developing innovative treatments and expanding its offerings in the biopharmaceutical sector [2]

Investment Rating - The industry investment rating is "Positive" [1][23] Core Viewpoints - External risks are controllable, and innovative drugs remain an important investment theme. The report suggests that the commercial value of innovative drugs is being realized smoothly, with biotech and biopharma operational efficiency continuously improving. The long-term outlook indicates that Chinese companies are significantly enhancing their position in the global innovative drug supply chain, with increasing source innovation capabilities [5][16]. Summary by Sections 1. Source Innovation Capability and External Risks - In the first half of 2025, the transaction amount related to the pharmaceutical sector in China reached 60.8 billion USD, a year-on-year increase of 129%, with 144 transactions, up 67% year-on-year. China's share in global pharmaceutical transactions was 46.63% in amount and 31.58% in number [6][8]. - The report emphasizes that U.S. government restrictive policies will have limited impact on the overseas market expansion of Chinese innovative drugs due to the collaborative interests of multinational corporations (MNCs) and biotech firms [5][8]. 2. Commercialization Value of Innovative Drugs - The report analyzed 19 representative large pharmaceutical companies, which collectively generated revenue of 139.5 billion CNY in the first half of 2025, with a net profit of 25.4 billion CNY, showing stability. Notably, innovative drug revenues are growing rapidly, with companies like Hengrui Medicine and Hansoh Pharmaceutical showing significant increases in their innovative drug sales [10][12]. 3. Investment Recommendations - The report suggests selecting stocks based on validated R&D and commercialization capabilities, including industry leaders like Hengrui Medicine and 3SBio. Companies that are entering a performance release phase, such as Eddingpharm and Kangzhe Pharmaceutical, are also recommended. Additionally, it highlights event-driven or valuation-sensitive stocks like Innovent Biologics and Genscript Biotech [16].

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025. This drug is an anti-infective medication used for treating adult patients with invasive aspergillosis and invasive mucormycosis [1]. Company Summary - Yifan Pharmaceutical's subsidiary, Hefei Yifan Biopharmaceutical, has been granted approval for injectable isavuconazole, indicating a significant milestone in expanding its product portfolio in the anti-infective segment [1]. - The approval of injectable isavuconazole positions the company to address critical medical needs in treating serious fungal infections, potentially enhancing its market presence and revenue streams [1]. Industry Summary - The approval of injectable isavuconazole reflects ongoing advancements in the pharmaceutical industry, particularly in the development of treatments for invasive fungal infections, which are increasingly recognized as significant health threats [1]. - The introduction of new anti-infective drugs like isavuconazole is crucial for improving patient outcomes and addressing the growing concerns over fungal infections in immunocompromised populations [1].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, which is an anti-infection drug used for treating invasive fungal infections in adults [1] Company Summary - The injection of Sulfate Isavuconazole is specifically indicated for the treatment of invasive aspergillosis and invasive mucormycosis [1] - As of the date of the report, a total of 9 companies in China have received approval for the injection of Sulfate Isavuconazole, with several others undergoing review for generic drug applications [1] - The company has invested approximately 7.8972 million yuan in the research and development of Sulfate Isavuconazole [1]

Core Viewpoint - The company has received approval for its injectable drug, Isavuconazole sulfate, from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable Isavuconazole sulfate on September 15, 2025 [1] - Isavuconazole sulfate is an anti-infective medication indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1]

Core Viewpoint - The company received approval for its injectable drug Isavuconazole from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Company Summary - Yifan Pharmaceutical's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. obtained the drug registration certificate for injectable Isavuconazole on September 15, 2025 [1] - Isavuconazole is an antifungal medication indicated for the treatment of invasive infections in adult patients, specifically invasive aspergillosis and invasive mucormycosis [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2025-059 亿帆医药股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司合肥亿帆生物制药 有限公司于2025年9月15日收到国家药品监督管理局核准签发的注射用硫酸艾沙 康唑《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 1、药品名称：注射用硫酸艾沙康唑 2、剂型：注射剂 3、申请事项：药品注册（境内生产） 4、注册分类：化学药品4类 5、规格：0.2g（按C22H17F2N5OS计） 6、药品受理号：CYHS2401734 7、证书编号：2025S02842 8、药品批准文号：国药准字H20255440 品注册证书》。 9、药品批准文号有效期：至2030年09月08日 10、上市许可持有人：合肥亿帆生物制药有限公司 11、生产企业：合肥亿帆生物制药有限公司 12、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、产品简介 ...

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) announced the approval of its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. for the injection of Sulfate Isavuconazole by the National Medical Products Administration [1] - The approved drug, Sulfate Isavuconazole, is an anti-infective medication [1] - It is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1]

Core Insights - The Chinese innovative drug sector has become a hot area in the capital market this year, driven by the real demand for high-quality innovative drugs from domestic patients, which is seen as the core driver for industry recovery [1] Group 1: Market Performance - In the first half of this year, 21 innovative drug companies listed on A-shares achieved a revenue of 28.69 billion yuan, a year-on-year increase of approximately 42%, while 32 innovative drug companies listed on H-shares reported a revenue of 42.13 billion yuan, a year-on-year increase of about 10% [2] - Leading companies have shown particularly strong performance, with Heng Rui Medicine's innovative drug sales revenue reaching 7.57 billion yuan, a year-on-year increase of approximately 14.5% [2] - Innovative drugs from Bai Jie Shen Zhou, such as Bai Yue Ze and Bai Ze An, reported sales of 1.192 billion yuan and 2.643 billion yuan respectively, with year-on-year growth rates of 36.5% and 20.6% [2] Group 2: Policy and Market Dynamics - The Chinese innovative drug market is entering a dual development cycle with domestic medical insurance and overseas markets, leading to a gradual path to profitability for companies [2] - Since its establishment in 2018, the National Medical Insurance Bureau has included 149 innovative drugs in the medical insurance catalog through seven rounds of adjustments, significantly optimizing the clinical medication structure [3] - By May 2025, the medical insurance fund is expected to pay a cumulative 410 billion yuan for negotiated drugs, driving related drug sales to exceed 600 billion yuan [3] Group 3: Future Outlook - The innovative drug market in China is projected to reach a scale of 162 billion yuan by 2024, with medical insurance payments accounting for approximately 43.8% [4] - The commercial success of innovative drugs is seen as a starting point for higher-level research and development, with many companies increasing their R&D investments despite revenue growth [4] - China currently holds a 30% share in global drug research and development, with 1,775 first-in-class drug pipelines, representing 19% of the global total [4]

Core Viewpoint - The Chinese innovative drug sector has shown remarkable performance in the capital market this year, driven by record-high business development (BD) amounts for overseas expansion and a rapid growth in domestic revenue, indicating a shift from a "cash-burning" model to a "cash cow" model [1][2]. Group 1: Domestic Demand - The demand for high-quality innovative drugs in China is continuously being released, with A-share innovative drug companies achieving a revenue of 28.69 billion yuan in the first half of the year, a year-on-year increase of approximately 42% [2]. - Leading companies like Heng Rui Medicine reported a 14.5% increase in innovative drug sales revenue to 7.57 billion yuan, primarily from the domestic market [2]. - Other companies such as Bai Jie Shen Zhou and Yi Fan Medicine also reported significant revenue growth, with Bai Jie Shen Zhou's flagship product achieving a 36.5% increase in sales [3]. Group 2: Policy Support - The Chinese government has been actively supporting the development of innovative drugs, with 149 innovative drugs included in the national medical insurance directory since 2018 [4]. - The National Healthcare Security Administration has indicated that by May 2025, the cumulative payment for negotiated drugs will reach 410 billion yuan, driving related drug sales to exceed 600 billion yuan [4]. - New policies are being introduced to address pricing and reimbursement challenges for innovative drugs, including the establishment of a commercial health insurance directory for innovative drugs [5]. Group 3: Research and Development Investment - Despite revenue growth, many innovative drug companies are increasing their R&D investments, creating a positive cycle of revenue growth leading to increased R&D and a rich pipeline [7]. - Heng Rui Medicine invested 3.87 billion yuan in R&D, with over 100 innovative products in clinical development [7]. - The overall trend indicates that companies are focusing on building a robust pipeline to sustain future revenue growth [7]. Group 4: Global Positioning - China currently holds nearly 30% of the global drug R&D market share, with a significant number of first-in-class drug pipelines [8]. - The country has become an important source of global pharmaceutical innovation, with a notable increase in technology licensing and overseas expansion [8]. - The past years of investment during the "innovation drug bubble" period are expected to yield significant results in the coming years [8].